Thyssen JP - Search Results

1

Evaluating oral roflumilast in patients with hidradenitis suppurativa previously exposed to biologic treatment.

Holgersen N, Nielsen VW, Ring HC, Egeberg A, Thyssen JP, Gyldenløve M, Thomsen SF. Holgersen N, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2024 Dec 18. doi: 10.1111/jdv.20515. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39692433 No abstract available.

2

Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.

Ring HC, Maul JT, Yao Y, Wu JJ, Thyssen JP, Thomsen SF, Egeberg A. Ring HC, et al. Among authors: thyssen jp. JAMA Dermatol. 2022 Feb 1;158(2):184-188. doi: 10.1001/jamadermatol.2021.4805. JAMA Dermatol. 2022. PMID: 34851360 Free PMC article.

3

Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?

Ring HC, Frew JW, Thyssen JP, Egeberg A, Thomsen SF. Ring HC, et al. Among authors: thyssen jp. Clin Exp Dermatol. 2022 Aug;47(8):1585-1586. doi: 10.1111/ced.15232. Epub 2022 Jun 3. Clin Exp Dermatol. 2022. PMID: 35437813 No abstract available.

4

Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy.

Gyldenløve M, Zachariae C, Thyssen JP, Egeberg A. Gyldenløve M, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e765-e766. doi: 10.1111/jdv.18275. Epub 2022 Jun 14. J Eur Acad Dermatol Venereol. 2022. PMID: 35620947 No abstract available.

5

Attitudes towards clinical research in adult patients with hidradenitis suppurativa during the COVID-19 pandemic: Insights from a survey.

Holgersen N, Nielsen VW, Ali Z, Brøgger-Mikkelsen M, Flege MM, Thyssen JP, Egeberg A, Thomsen SF. Holgersen N, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2024 May;38(5):e371-e373. doi: 10.1111/jdv.19758. Epub 2023 Dec 18. J Eur Acad Dermatol Venereol. 2024. PMID: 38108515 No abstract available.

6

Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long-term use.

Egeberg A, Thyssen JP. Egeberg A, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2024 Jul;38(7):1236-1237. doi: 10.1111/jdv.20041. J Eur Acad Dermatol Venereol. 2024. PMID: 38923647 No abstract available.

7

Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa.

Holgersen N, Nielsen VW, Ring HC, Egeberg A, Thyssen JP, Gyldenløve M, Thomsen SF. Holgersen N, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2024 Jul 1. doi: 10.1111/jdv.20222. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38949093 No abstract available.

8

Impact of the pre-biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study.

Thein D, Nielsen ML, Maul JT, Thomsen SF, Thyssen JP, Egeberg A. Thein D, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2024 Jul 25. doi: 10.1111/jdv.20259. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39051535

9

Low prevalence of positive skin pathergy testing in Danish patients with Behçet's disease.

Gyldenløve M, Tvede N, Larsen JL, Jacobsen S, Thyssen JP. Gyldenløve M, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2014 Feb;28(2):259-60. doi: 10.1111/jdv.12189. Epub 2013 May 16. J Eur Acad Dermatol Venereol. 2014. PMID: 23676001 No abstract available.

10

Skin cancer in patients with psoriasis.

Egeberg A, Thyssen JP, Gislason GH, Skov L. Egeberg A, et al. Among authors: thyssen jp. J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1349-53. doi: 10.1111/jdv.13619. Epub 2016 Mar 2. J Eur Acad Dermatol Venereol. 2016. PMID: 26932589

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

719 results

Search Page

Filters